Results 121 to 130 of about 43,675 (258)

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

Myelodysplasia‐Related Gene Mutation Burden Is Associated With Complete Remission After Induction Therapy in Acute Myeloid Leukemia, Not Otherwise Specified: Reclassification According to the Updated Classifications

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Updated classifications incorporating myelodysplasia‐related (MR) gene mutations reclassify many cases previously diagnosed as acute myeloid leukemia, not otherwise specified (AML, NOS). We evaluated the clinical significance of MR gene mutation burden, defined by mutation number and variant allele frequency (VAF), in AML, NOS ...
Taegeun Lee   +10 more
wiley   +1 more source

Biomarkers Correlating With the Development of Oral Squamous Cell Carcinoma From Leukoplakia

open access: yesOral Diseases, EarlyView.
ABSTRACT Background We assessed protein biomarkers expressed in oral leukoplakia (OL) that are associated with the risk of transformation into oral squamous cell carcinoma (OSCC). Methods Tissue sections of OL transforming into OSCC (leuko‐ca), the corresponding OSCC and OL that did not progress to OSCC (leuko‐nonca) were analyzed with global relative ...
Daniel Giglio   +8 more
wiley   +1 more source

Predicting Relevant Microglia‐Associated Cell–Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1

open access: yesGlia, Volume 74, Issue 10, October 2026.
We used CellChat to infer altered cell–cell communication in Alzheimer's disease Microglia signal to each other via SPP1 in Alzheimer's disease. SPP1‐expressing microglia are present around amyloid‐β plaques. ABSTRACT Microglia play a key role in the pathophysiology of Alzheimer's Disease (AD) and their increased heterogeneity likely affects disease ...
Janssen M. Kotah   +7 more
wiley   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

open access: yesInternational Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer   +8 more
wiley   +1 more source

EZH2 moves [PDF]

open access: yesScience-Business eXchange, 2012
openaire   +1 more source

Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis. [PDF]

open access: yesCell Death Dis
Ma M   +25 more
europepmc   +1 more source

The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B–BCL6 Regulatory Circuit in Burkitt Lymphoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1535-1545, 15 September 2026.
MEF2B and BCL6 have established functions in germinal center B‐cell biology and lymphomagenesis. The mechanism of MEF2B deregulation and its significance for cell survival in Burkitt lymphoma however remain unclear. This study highlights MEF2B as a crucial transcription factor in Burkitt lymphoma and suggests ZDHHC11 as an upstream regulator of MEF2B ...
Lotteke J. Y. M. Ziel‐Swier   +12 more
wiley   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima   +48 more
wiley   +1 more source

Home - About - Disclaimer - Privacy